<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813774</url>
  </required_header>
  <id_info>
    <org_study_id>RA0003</org_study_id>
    <secondary_id>Eudract no. 2007-006344-22</secondary_id>
    <nct_id>NCT00813774</nct_id>
  </id_info>
  <brief_title>Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers</brief_title>
  <official_title>Open, Randomized, Parallel Group, Single Dose, Bioavailability Comparison of 3 Certolizumab Pegol Solution Formulations (Lyophilized, Liquid, Pre-filled Syringe Formulation) to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the bioavailability of a single dose of certolizumab pegol solutions given
      subcutaneously either by one of the three formulations and to investigate safety and
      tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time 0 to infinity (AUC)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time 0 to the last quantifiable point (AUC(0-t),)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time point where log-linear elimination phase begins (TLIN )</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest quantifiable concentration time (LQCT)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination rate constant (Î»z)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time corresponding to Cmax (tmax)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total body clearance (CL/F)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of distribution (Vz/F)</measure>
    <time_frame>PK samples: from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapolated portion of the AUC (AUC_ext )</measure>
    <time_frame>PK samples; from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with anti-certolizumab pegol antibody plasma level &gt;2.4 units/mL</measure>
    <time_frame>PK samples; from pre-dose to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Bioavailability Study on Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized formulation (reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid Formulation (test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-filled Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-filled syringe (test)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Cimzia</other_name>
    <other_name>CDP870</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg</description>
    <arm_group_label>Liquid</arm_group_label>
    <other_name>Cimzia</other_name>
    <other_name>CDP870</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
    <description>200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg</description>
    <arm_group_label>Pre-filled Syringe</arm_group_label>
    <other_name>Cimzia</other_name>
    <other_name>CDP870</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers aged between 18 and 55

          -  Body Mass Index (BMI) between 18 and 30 kg/m2 with normal laboratory data

          -  negative for Tuberculosis test

          -  normal Electrocardiogram (ECG)

          -  adequate contraception for females

          -  given informed consent

        Exclusion Criteria:

          -  Any significant abnormality in medical history, physical examination, laboratory
             testing

          -  Intake of concomitant medication

          -  smoking more than 10 cigarettes per day

          -  alcohol or drug abuse

          -  pregnancy or breast feeding

          -  history of tuberculosis

          -  participation in another trial within 3 months prior to this study

          -  previous administration of certolizumab pegol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rueil Malmaison</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/RA0003_CSS_20081130.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cimzia</keyword>
  <keyword>certolizumab pegol</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

